Abstract Background In Belgium, COVID-19 epidemy began on February 4, 2020 with a peak on April 10, 2020. Patients with cystic fibrosis (CF) followed in the Cliniques universitaires Saint-Luc were rapidly isolated before the government lockdown. Methods After the peak of the epidemy, we measured anti-SARS-CoV-2 IgM and IgG antibodies in 149 patients and collected clinical data. Results Only 3 asymptomatic patients presented IgG against the virus. In one patient hospitalized for COVID-19 (positive molecular testing), we did not detect any anti-SARS-CoV-2 antibodies, as in thirty-five other symptomatic patients considered as possible cases. Conclusions Even if respiratory symptoms linked to CF are frequent and compatible with COVID-19, anti-SARS-CoV-2 IgG antibodies were detected only in 3 asymptomatic patients. This reassuring study concerning the risk of COVID-19 in patients with CF illustrates the difficulty to distinguish COVID-19 symptoms from respiratory exacerbations and the need of generalized molecular testing to make a precise diagnosis.

中文翻译：

---

比利时囊性纤维化患者队列中的 SARS-CoV-2 血清阳性率

摘要 背景在比利时，COVID-19 流行病始于 2020 年 2 月 4 日，并在 2020 年 4 月 10 日达到高峰。在政府封锁之前，在圣吕克临床大学跟踪的囊性纤维化 (CF) 患者被迅速隔离。方法 流行高峰后，我们检测了 149 名患者的抗 SARS-CoV-2 IgM 和 IgG 抗体并收集了临床数据。结果 只有 3 名无症状患者出现了针对病毒的 IgG。在一名因 COVID-19（阳性分子检测）住院的患者中，我们没有检测到任何抗 SARS-CoV-2 抗体，与其他 35 名被视为可能病例的有症状患者一样。结论 即使与 CF 相关的呼吸道症状频繁出现且与 COVID-19 相符，但仅在 3 名无症状患者中检测到抗 SARS-CoV-2 IgG 抗体。